Farmaceutica REMEDIA S.A.: A Closer Look at the Special Delegation for the EGMS 2024
As part of its ongoing strategic initiatives, Farmaceutica REMEDIA S.A. has outlined a series of key proposals for consideration and approval at the Extraordinary General Meeting of Shareholders (EGMS) slated for August 2024. The pivotal meeting is scheduled to convene at precisely 12.00 o’clock at the company’s headquarters situated on N. Balcescu Blvd, no. 2, in Deva, Hunedoara County, with the subsequent meeting, if necessary, occurring on the following day, August 22nd, 2024, at the same location and time.
Key Proposals for Shareholder Voting
The agenda for the forthcoming EGMS encompasses significant financial strategies that are poised to influence the future trajectory of Farmaceutica REMEDIA S.A. Shareholders are invited to deliberate and vote on the following propositions, with the end goal of fostering robust growth and enhanced financial agility for the company:
1. Expansion of the Credit Facility with Banca Transilvania S.A.
One of the major items on the agenda includes the proposal to augment the credit facility currently extended to the company by Banca Transilvania S.A. This move involves raising the Global Operating Ceiling from RON 90,000,000 to an impressive RON 100,000,000. This strategic financial maneuver is aimed at providing Farmaceutica REMEDIA S.A. with the requisite financial bandwidth to fuel its growth objectives and operational needs. Moreover, the proposal encompasses securing the expanded credit line with adequate collaterals, which may comprise receivables, inventories, real estate, and blank promissory notes/guarantees, potentially surpassing the 20% threshold of the company’s total fixed assets, less receivables.
2. Delegation of Authority to Mr. Cristian Plocon
In the spirit of operational efficiency and effective management of the expanded credit facility, the agenda also proposes the delegation of authority to Mr. Cristian Plocon, a distinguished member of the Board of Administrators of Farmaceutica REMEDIA S.A. This authorization would enable Mr. Plocon to sign off on the credit contract(s) and any appendices thereto, alongside any mortgage and/or real estate contracts with the chosen bank. Furthermore, this empowerment extends to signing any other requisite documents demanded by the bank(s) or notary for the finalization and execution of the said credit contracts.
3. Empowerment of the Board of Administrators
Last but certainly not least, the shareholders are invited to empower the Board of Administrators with the discretion to issue Decisions pursuant to the aforementioned Items 1 and 2. This includes detailing the operational modalities for the extension of the credit facility granted to Farmaceutica REMEDIA S.A., thereby ensuring that the administration has the necessary authority to act decisively and in the best interest of the company.
This forthcoming EGMS stands as a vital platform for shareholder involvement in the fundamental decision-making processes that shape the future of Farmaceutica REMEDIA S.A. The proposals underscore the company’s commitment to strategic financial planning and operational excellence. Shareholders’ active participation and voting on these crucial matters will significantly contribute to the company’s directional strategy and its enduring success in the dynamic pharmaceutical industry.
As Farmaceutica REMEDIA S.A. embarks on these and other strategic initiatives, it remains steadfast in its mission to deliver excellence in pharmaceutical services and healthcare solutions, continually reinforcing its market presence and providing value to its shareholders and customers alike.
